RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 1/Phase 2

Registered title, quoted from ClinicalTrials.gov

GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteNational Cancer Center / Cancer Hospital, CAMS中国医学科学院肿瘤医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07738341, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically confirmed locally advanced unresectable or metastatic breast cancer (Triple-Negative Breast Cancer [TNBC] or Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative [HR+/HER2-]).

    Inclusion criterion 2

  3. No prior treatment with any immune checkpoint inhibitor (e.g., anti-Programmed Death-1 [PD-1], anti-Programmed Death-Ligand 1 [PD-L1], anti-Cytotoxic T-Lymphocyte-Associated Protein 4 [CTLA-4]) or Programmed Death-1/Vascular Endothelial Growth Factor [PD-1/VEGF] bispecific antibody, except for adjuvant therapy if relapse occurred ≥12 months after discontinuation.

    Inclusion criterion 4

    Unresolved toxicity from prior therapy > Grade 1 (except alopecia or Grade ≤2 hypothyroidism stable on hormone replacement).

    Exclusion criterion 4

    Prior immune-related adverse events [irAEs] ≥ Grade 3 leading to treatment discontinuation.

    Exclusion criterion 5

  4. Eastern Cooperative Oncology Group [ECOG] performance status 0 or 1.

    Inclusion criterion 6

  5. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1].

    Inclusion criterion 3

  6. History of other malignancies within 3 years (except cured non-melanoma skin cancer or carcinoma in situ).

    Exclusion criterion 7

    Positive for Hepatitis B Virus [HBV] surface antigen [HBsAg] or core antibody [HBcAb] with HBV-Deoxyribonucleic Acid [DNA] > 500 IU/mL; or positive Hepatitis C Virus [HCV] antibody with HCV-Ribonucleic Acid [RNA] above the lower limit of quantification.

    Exclusion criterion 19

    Known primary immunodeficiency or positive Human Immunodeficiency Virus [HIV] antibody.

    Exclusion criterion 20

  7. Pregnant or breastfeeding women.

    Exclusion criterion 22

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07738341, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Cohort-Specific Requirements:

Cohort A: Histologically confirmed locally advanced unresectable or metastatic Triple-Negative Breast Cancer [TNBC]; no prior systemic therapy for advanced disease; prior adjuvant/neoadjuvant taxane allowed if recurrence ≥6 months after last taxane dose; no prior Trop-2 Antibody-Drug Conjugate [ADC].

Cohort B: Histologically confirmed locally advanced unresectable or metastatic TNBC; no prior systemic therapy for advanced disease; prior adjuvant/neoadjuvant taxane allowed if recurrence ≥12 months after last taxane dose.

Cohort E: Histologically confirmed locally advanced unresectable or metastatic HR+/HER2- breast cancer; disease progression after ≥1 line of endocrine therapy (aromatase inhibitor and/or fulvestrant) and CDK4/6i in advanced setting; received ≥1 line of systemic chemotherapy in advanced setting; no prior Trop-2 ADC.

Cohort F: Histologically confirmed locally advanced unresectable or metastatic HR+/HER2- breast cancer; disease progression after ≥1 line of endocrine therapy and CDK4/6i with primary or secondary endocrine resistance; prior adjuvant/neoadjuvant taxane allowed if recurrence ≥12 months after last taxane dose.

Cohort G: Histologically confirmed locally advanced unresectable or metastatic HR+/HER2- breast cancer; prior CDK4/6i and endocrine therapy in any setting; received a TROP2 or HER2 ADC in advanced setting.

Inclusion Criteria:

  • Age ≥ 18 years, male or female.
  • Histologically confirmed locally advanced unresectable or metastatic breast cancer (Triple-Negative Breast Cancer [TNBC] or Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative [HR+/HER2-]).
  • At least one measurable lesion per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v1.1].
  • No prior treatment with any immune checkpoint inhibitor (e.g., anti-Programmed Death-1 [PD-1], anti-Programmed Death-Ligand 1 [PD-L1], anti-Cytotoxic T-Lymphocyte-Associated Protein 4 [CTLA-4]) or Programmed Death-1/Vascular Endothelial Growth Factor [PD-1/VEGF] bispecific antibody, except for adjuvant therapy if relapse occurred ≥12 months after discontinuation.
  • Assessed by the investigator as suitable for the assigned combination therapy.
  • Eastern Cooperative Oncology Group [ECOG] performance status 0 or 1.
  • Life expectancy ≥ 3 months.
  • Adequate organ function (within 14 days before first dose, without transfusion or Granulocyte Colony-Stimulating Factor [G-CSF] support): Hemoglobin ≥ 9 g/dL, Absolute Neutrophil Count [ANC] ≥ 1.5×10\^9/L, Platelets ≥ 100×10\^9/L; Aspartate Aminotransferase [AST] and Alanine Aminotransferase [ALT] ≤ 3×Upper Limit of Normal [ULN] (≤5×ULN if liver metastases); Alkaline Phosphatase [ALP] ≤ 2.5×ULN (≤5×ULN if bone or liver metastases); Total Bilirubin ≤ 1.5×ULN (≤3×ULN for Gilbert's Syndrome); Serum Creatinine ≤ 1.5×ULN or Creatinine Clearance ≥ 50 mL/min (Cockcroft-Gault formula); Urine protein dipstick ≤ 1+ (if ≥2+, 24-hour urine protein quantification < 1 g); Coagulation function: International Normalized Ratio [INR] or activated Partial Thromboplastin Time [aPTT] ≤ 1.5×ULN (for patients not on anticoagulation therapy).
  • Provide a Formalin-Fixed Paraffin-Embedded [FFPE] tumor tissue sample for biomarker testing.
  • Effective contraception for fertile participants.

Exclusion Criteria:

  • Prior anti-cancer therapy within specified washout periods.
  • Systemic immunosuppressive therapy within 2 weeks before first dose.
  • Major surgery or significant traumatic injury within 4 weeks before first dose.
  • Unresolved toxicity from prior therapy > Grade 1 (except alopecia or Grade ≤2 hypothyroidism stable on hormone replacement).
  • Prior immune-related adverse events [irAEs] ≥ Grade 3 leading to treatment discontinuation.
  • Active Central Nervous System [CNS] metastases (except stable asymptomatic lesions).
  • History of other malignancies within 3 years (except cured non-melanoma skin cancer or carcinoma in situ).
  • Uncontrolled pleural effusion or ascites requiring repeated drainage.
  • Clinically significant cardiovascular disease (e.g., myocardial infarction, unstable angina, stroke within 6 months; QTcF prolongation; New York Heart Association [NYHA] Class II-IV heart failure; pericarditis/myocarditis).
  • History of Interstitial Lung Disease [ILD] or non-infectious pneumonitis requiring steroids.
  • Active or history of autoimmune disease requiring systemic treatment in the past 2 years.
  • History of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea).
  • History of hypertensive crisis or hypertensive encephalopathy.
  • Severe coagulation disorders or significant bleeding risk (e.g., severe vascular disease, hemoptysis, intracranial/spinal hemorrhage, tumor invading major vessels).
  • History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess.
  • Active infection requiring systemic anti-infective therapy within 2 weeks; severe infection within 4 weeks.
  • Uncontrolled intercurrent illness (e.g., poorly controlled hypertension or Type 2 diabetes mellitus).
  • Known active tuberculosis [TB].
  • Positive for Hepatitis B Virus [HBV] surface antigen [HBsAg] or core antibody [HBcAb] with HBV-Deoxyribonucleic Acid [DNA] > 500 IU/mL; or positive Hepatitis C Virus [HCV] antibody with HCV-Ribonucleic Acid [RNA] above the lower limit of quantification.
  • Known primary immunodeficiency or positive Human Immunodeficiency Virus [HIV] antibody.
  • History of solid organ or hematopoietic stem cell transplantation (except corneal transplant).
  • Pregnant or breastfeeding women.
  • Known hypersensitivity to GB268 or its excipients; history of severe hypersensitivity to other monoclonal antibodies.
  • Any other condition that would make the participant unsuitable for the study.
  • History of severe hypersensitivity to other drugs in the combination regimen.

Quoted from ClinicalTrials.gov, NCT07738341, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07738341, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07738341